304,529 Shares in Henry Schein, Inc. $HSIC Bought by Nuveen LLC

Key Points

• Nuveen LLC acquired 304,529 shares of Henry Schein, Inc., valued at approximately $20.86 million, which represents a 0.25% stake in the company.
• Henry Schein reported a quarterly EPS of $1.10, missing estimates and reflecting a 3.3% increase in revenue year-over-year, despite a decline from the previous year's EPS of $1.23.
• Analysts have downgraded Henry Schein's stock ratings, with the consensus target price now at $75.58 and a majority rating of "Hold."

Nuveen LLC acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 304,529 shares of the company's stock, valued at approximately $20,857,000. Nuveen LLC owned 0.25% of Henry Schein at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in HSIC. Palestra Capital Management LLC bought a new position in shares of Henry Schein during the fourth quarter valued at $182,988,000. Steadfast Capital Management LP increased its holdings in Henry Schein by 254.2% in the fourth quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company's stock valued at $113,336,000 after purchasing an additional 1,175,408 shares during the period. Hudson Bay Capital Management LP increased its holdings in Henry Schein by 102.1% in the fourth quarter. Hudson Bay Capital Management LP now owns 1,465,007 shares of the company's stock valued at $101,378,000 after purchasing an additional 740,007 shares during the period. Ananym Capital Management LP bought a new position in Henry Schein during the 4th quarter worth $32,628,000. Finally, Millennium Management LLC lifted its holdings in Henry Schein by 451.7% during the 4th quarter. Millennium Management LLC now owns 497,554 shares of the company's stock worth $34,431,000 after buying an additional 407,376 shares during the period. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Price Performance

Shares of NASDAQ:HSIC traded up $1.39 during trading on Friday, reaching $69.60. The company had a trading volume of 1,436,378 shares, compared to its average volume of 2,109,852. The company has a current ratio of 1.41, a quick ratio of 0.78 and a debt-to-equity ratio of 0.51. The company has a fifty day moving average of $70.55 and a two-hundred day moving average of $70.45. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The stock has a market capitalization of $8.44 billion, a P/E ratio of 22.45, a price-to-earnings-growth ratio of 2.25 and a beta of 0.81.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.09). The firm had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. Henry Schein's revenue for the quarter was up 3.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.23 earnings per share. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. Equities research analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HSIC has been the subject of a number of recent analyst reports. Stifel Nicolaus reissued a "hold" rating and set a $75.00 target price (down previously from $80.00) on shares of Henry Schein in a research report on Friday, July 25th. Barrington Research reduced their price objective on Henry Schein from $86.00 to $78.00 and set an "outperform" rating for the company in a research note on Wednesday, August 6th. Baird R W lowered shares of Henry Schein from a "strong-buy" rating to a "hold" rating in a report on Monday, July 14th. UBS Group reduced their target price on shares of Henry Schein from $75.00 to $70.00 and set a "neutral" rating for the company in a research note on Wednesday, August 6th. Finally, Piper Sandler decreased their target price on Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a research report on Wednesday, April 30th. Four research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat, Henry Schein has a consensus rating of "Hold" and an average price target of $75.58.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.